Methods and compositions for preserving retinal ganglion cells
First Claim
1. A method of preserving visual function of an eye of a subject with an ocular condition selected from the group consisting of glaucoma, optic nerve injury, and optic neuritis, wherein a symptom of the ocular condition is the loss of retinal ganglion cell viability in the retina of the eye with the condition, the method comprising:
- (a) administering to the eye of the subject an effective amount of a necrosis inhibitor selected from the group consisting of necrostatin-1, necrostatin-2, necrostatin-3, necrostatin-4, necrostatin-5, necrostatin-7, and related compounds, and an effective amount of an apoptosis inhibitor selected from the group consisting of pan-caspase inhibitors, caspase-1 inhibitors, caspase-3 inhibitors, caspase-8 inhibitors, and caspase-9 inhibitors, thereby to preserve the viability of retinal ganglion cells disposed within the retina of the eye; and
(b) after step (a), measuring visual function of the eye.
1 Assignment
0 Petitions
Accused Products
Abstract
Provided are methods and compositions for maintaining the viability of retinal ganglion cells in a subject with an ocular disorder including, for example, glaucoma and optic nerve injury. The viability of the retinal ganglion cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells and/or promote axon regeneration, thereby minimizing the loss of vision or visual function associated with the ocular disorder.
-
Citations
26 Claims
-
1. A method of preserving visual function of an eye of a subject with an ocular condition selected from the group consisting of glaucoma, optic nerve injury, and optic neuritis, wherein a symptom of the ocular condition is the loss of retinal ganglion cell viability in the retina of the eye with the condition, the method comprising:
-
(a) administering to the eye of the subject an effective amount of a necrosis inhibitor selected from the group consisting of necrostatin-1, necrostatin-2, necrostatin-3, necrostatin-4, necrostatin-5, necrostatin-7, and related compounds, and an effective amount of an apoptosis inhibitor selected from the group consisting of pan-caspase inhibitors, caspase-1 inhibitors, caspase-3 inhibitors, caspase-8 inhibitors, and caspase-9 inhibitors, thereby to preserve the viability of retinal ganglion cells disposed within the retina of the eye; and (b) after step (a), measuring visual function of the eye. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
-
Specification